How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Is the proposed process for updating and withdrawing the TAs appropriate to achieve useful and usable guidance?

  • Question on Consultation

    Is the proposed process sufficiently clear? Are further details of the proposed process required by stakeholders?

  • Question on Consultation

    Should NICE consider adapting other elements of the proposed process to achieve more useful and usable guidance?

  • Question on Consultation

    Do you have any other comments on the proposed process for updating the TAs within the proportionate decision-making process?

  • Question on Consultation

    Would it be challenging to implement of any of the recommendations for the updated TAs? Please say why and for whom, and how these could be mitigated.

  • Question on Consultation

    Would implementation of any of the recommendations have significant cost implications?

Review proposal of TA288, TA315, TA336, TA390, TA418, TA572, TA583

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Rationale for change

  1. The NICE Centre for Guidelines is currently conducting a partial update of NICE guideline 28 (NG28) Type 2 diabetes in adults: management. NICE is updating our recommendations on drug therapy. The update will be published on 18 February 2026.

  2. The recommendations in the update to NG28 are inconsistent with the technology appraisals which cover the management of type 2 diabetes. This inconsistency needs to be resolved so that NICE can produce useful and usable recommendations.

  3. The changes to the evidence base and clinical pathway for drug therapies for treating type 2 diabetes in adults also impact the recommendation included in NICE TA924 (Tirzepatide for treating type 2 diabetes). The updates to TA924 are covered by a separate review proposal paper.